| Trial ID: | L6971 |
| Source ID: | NCT01681693
|
| Associated Drug: |
Metformin
|
| Title: |
Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans
|
| Acronym: |
#6113
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Healthy|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Metformin
|
| Outcome Measures: |
Primary: Renal Clearance of the Metformin, To test whether individuals with genetic variants of transporters OCT3 and MATE1 exhibit altered pharmacokinetics of metformin., 24 hours post-dose|Plasma glucose, To test whether individuals with genetic variants of transporters OCT3 and MATE1 exhibit altered glucose lowering response to metformin., 0, 15, 30, 45, 60, 90, 120, 180 minutes after glucose administration |
|
| Sponsor/Collaborators: |
Sponsor: University of California, San Francisco
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
33
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2010-02
|
| Completion Date: |
2013-07
|
| Results First Posted: |
|
| Last Update Posted: |
2014-10-23
|
| Locations: |
San Francisco General Hospital, San Francisco, California, 94110, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01681693
|
